Analyst Consensus ?
ConsensusHold37 ratings
Bullish1129.7%
Neutral2054.1%
Bearish616.2%
Molson Coors Beverage Company · TAP · FY2024 Q4 · Calendar Q1 2025
Molson Coors pairs premiumization with margin-focused portfolio changes
The call supports a measured growth case built on premiumization, mix, cash generation and newer beverage categories, but volume declines, tariff exposure and execution risks qualify the outlook.
Reported Before market openNYSEConsumer Defensive
$7.15B market cap
70quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.17
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.71B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+9.5%
Event window
SPY move
+1.1%
Same window
Abnormal move
+8.5%
Stock minus SPY
Volume
3.6×
Versus trailing sessions
Subsequent drift
+1.8%
Up to 20 sessions
TAPSPY benchmark
Ask FN2 about TAP FY2024 Q4
Transcript, numbers and history already loaded
What drove TAP's +9.5% move after FY2024 Q4 earnings?What changed in TAP's guidance and outlook in FY2024 Q4?Give me the bull and bear case for TAP after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management highlighted the exit of Pabst and Labatt contract-brewing volumes, a Fever-Tree U.S. partnership, Peroni on-shoring and continued investment in ZOA and Naked Life. These moves trade some near-term volume for margin and portfolio development.
Guidance delta
Management maintained 2025 guidance, targeting low-single-digit revenue growth and high-single-digit EPS growth.
Key takeaways
- Underlying EPS grew 9.2% year over year in Q4 while net sales were flat to slightly down.
- Free cash flow exceeded $1.2 billion, supporting a $369 million dividend and $643 million of repurchases.
- Contract-brewing exits create a 2025 volume headwind but are expected to improve margins.
Management priorities
- Advance premiumization and core-brand share gains.
- Expand non-alcoholic and ready-to-drink offerings, including ZOA and Naked Life.
- Execute Fever-Tree commercialization, Peroni U.S. on-shoring, and ZOA integration.
Follow TAP with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$38.41Current
$40Low
$53.88Average
$75High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 13, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Oct 5, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 10, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Needham | Buy | Buy | Maintain | Aug 7, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 14, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | May 5, 2026 |
| Barclays | Underweight | Underweight | Maintain | May 4, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Mar 30, 2026 |
| B of A Securities | Underperform | Neutral | Downgrade | Feb 25, 2026 |
| TD Cowen | Hold | Hold | Maintain | Feb 20, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Feb 19, 2026 |
| Roth Capital | Buy | Buy | Maintain | Nov 5, 2025 |
| Jefferies | Hold | Hold | Maintain | Nov 5, 2025 |
| Bernstein | Market Perform | Market Perform | Maintain | Nov 5, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 2, 2025 |
| Wedbush | Neutral | Neutral | Maintain | Nov 6, 2023 |
| Roth MKM | Buy | Buy | Maintain | Oct 4, 2023 |
| CFRA | Buy | Hold | Upgrade | May 2, 2023 |
| Credit Suisse | Underperform | Underperform | Maintain | Feb 22, 2023 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Jan 6, 2023 |
| Bryan Garnier | Sell | Buy | Downgrade | Sep 1, 2022 |
| Redburn Partners | Neutral | Sell | Upgrade | Jul 13, 2022 |
| MKM Partners | Buy | Buy | Maintain | Apr 6, 2020 |
| Guggenheim | Buy | Neutral | Upgrade | Mar 20, 2020 |
| BMO Capital | Market Perform | Outperform | Downgrade | Nov 26, 2019 |
| Redburn | Sell | Neutral | Downgrade | Oct 11, 2019 |
| Bank of America | Underperform | Buy | Downgrade | Jul 15, 2019 |
| Susquehanna | Positive | Positive | Maintain | Aug 2, 2018 |
| Stifel Nicolaus | Hold | Buy | Downgrade | May 17, 2018 |
| Stifel | Hold | Buy | Downgrade | May 17, 2018 |
| Berenberg | Hold | Sell | Upgrade | Feb 8, 2018 |
| Societe Generale | Hold | Buy | Downgrade | May 4, 2017 |
| Nomura | Neutral | Buy | Downgrade | Jun 23, 2015 |
| BTIG Research | Neutral | Buy | Downgrade | Sep 9, 2014 |
| BTIG | Neutral | Buy | Downgrade | Sep 9, 2014 |
| ISI Group | Buy | Neutral | Upgrade | May 16, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $38.41. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $45 | $43.04 | +17.2% | Aug 7, 2026 |
| Deutsche Bank | Analyst unavailable | $41 | $41.18 | +6.7% | Jul 22, 2026 |
| UBS | Analyst unavailable | $40 | $40.86 | +4.1% | Jul 16, 2026 |
| Wells Fargo | Analyst unavailable | $41 | $39.27 | +6.7% | Jul 8, 2026 |
| Morgan Stanley | Eric Serotta | $46 | $41.46 | +19.8% | May 4, 2026 |
| Barclays | Analyst unavailable | $41 | $42.14 | +6.7% | May 4, 2026 |
| Deutsche Bank | Steve Powers | $42 | $42.74 | +9.3% | May 1, 2026 |
| Barclays | Analyst unavailable | $43 | $44.54 | +12.0% | Apr 14, 2026 |
| UBS | Analyst unavailable | $52 | $49.21 | +35.4% | Feb 20, 2026 |
| Jefferies | Analyst unavailable | $45 | $48.17 | +17.2% | Feb 19, 2026 |
| Piper Sandler | Analyst unavailable | $45 | $50.81 | +17.2% | Feb 19, 2026 |
| Roth Capital | Analyst unavailable | $58 | $50.81 | +51.0% | Feb 19, 2026 |
| Wells Fargo | Analyst unavailable | $54 | $53.22 | +40.6% | Feb 17, 2026 |
| Barclays | Analyst unavailable | $49 | $49.05 | +27.6% | Jan 16, 2026 |
| BNP Paribas | Analyst unavailable | $40 | $50.64 | +4.1% | Jan 16, 2026 |
| UBS | Analyst unavailable | $50 | $49.64 | +30.2% | Jan 14, 2026 |
| Piper Sandler | Analyst unavailable | $50 | $45.47 | +30.2% | Nov 21, 2025 |
| Wells Fargo | Analyst unavailable | $50 | $46.45 | +30.2% | Nov 19, 2025 |
| Evercore ISI | Robert Ottenstein | $50 | $44.67 | +30.2% | Nov 5, 2025 |
| Roth Capital | Analyst unavailable | $65 | $44.83 | +69.2% | Nov 5, 2025 |
| Jefferies | Kaumil Gajrawala | $48 | $43.67 | +25.0% | Nov 4, 2025 |
| Needham | Analyst unavailable | $54 | $43.31 | +40.6% | Nov 3, 2025 |
| UBS | Peter Grom | $49 | $45.85 | +27.6% | Oct 8, 2025 |
| Piper Sandler | Michael Lavery | $52 | $45.76 | +35.4% | Sep 30, 2025 |
| Roth Capital | William Kirk | $71 | $56.95 | +84.8% | May 20, 2025 |
| Barclays | Lauren Lieberman | $61 | $60.96 | +58.8% | Mar 27, 2025 |
| Wells Fargo | Chris Carey | $74 | $60.03 | +92.7% | Nov 8, 2024 |
| Piper Sandler | Michael Lavery | $59 | $52.1 | +53.6% | Aug 7, 2024 |
| Piper Sandler | Michael Lavery | $57 | $53.07 | +48.4% | Jul 19, 2024 |
| Barclays | Lauren Lieberman | $47 | $53.98 | +22.4% | Jul 18, 2024 |
| Bernstein | Trevor Stirling | $61 | $51.24 | +58.8% | Jul 14, 2024 |
| Evercore ISI | Robert Ottenstein | $68 | $57.26 | +77.0% | Apr 30, 2024 |
| Barclays | Lauren Lieberman | $67 | $67.81 | +74.4% | Apr 12, 2024 |
| Goldman Sachs | Bonnie Herzog | $75 | $66.63 | +95.3% | Apr 9, 2024 |
| Piper Sandler | Michael Lavery | $69 | $67.24 | +79.6% | Mar 22, 2024 |
| Cowen & Co. | Analyst unavailable | $60 | $49.58 | +56.2% | Jan 6, 2023 |
| Deutsche Bank | Steve Powers | $50 | $54.5 | +30.2% | Dec 6, 2022 |
| Bryan Garnier & Co Ltd | Nikolaas Faes | $54 | $51.67 | +40.6% | Sep 1, 2022 |
| Goldman Sachs | Bonnie Herzog | $54 | $55.38 | +40.6% | Jun 28, 2022 |
| Cowen & Co. | Vivien Azer | $55 | $55.86 | +43.2% | Jun 24, 2022 |
| Deutsche Bank | Analyst unavailable | $51 | $54.25 | +32.8% | Apr 27, 2022 |
| MKM Partners | William Kirk | $64 | $49.05 | +66.6% | Feb 24, 2022 |
| Cowen & Co. | Vivien Azer | $50 | $44.5 | +30.2% | Nov 1, 2021 |
| Goldman Sachs | Bonnie Herzog | $42 | $43.42 | +9.3% | Oct 29, 2021 |
| Evercore ISI | Robert Ottenstein | $55 | $43.42 | +43.2% | Oct 29, 2021 |
| Guggenheim | Laurent Grandet | $75 | $48.31 | +95.3% | Jul 29, 2021 |
| Bernstein | Trevor Stirling | $74 | $56.47 | +92.7% | May 24, 2021 |
Track every rating change on TAP the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMolson Coors Beverage Company is a global entity engaged in the production, marketing, and sale of a diverse range of beer and other malt-based beverages. Its extensive operations span the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company's product lineup also features flavored malt beverages, craft beers, and convenient ready-to-drink selections. Founded in 1774, the firm, headquartered in Golden, Colorado, was previously known as Molson Coors Brewing Company before officially adopting its current name, Molson Coors Beverage Company, in January 2020.
Historical context
All TAP earningsConsumer Defensive peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PEP PepsiCo, Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.2% | +3.7% | PepsiCo: International Growth Offsets U.S. Soft-Drink and Margin Pressure |
| STZ Constellation Brands, Inc. | FY2027 Q2 · Calendar Q4 2026 | +5.4% | +2.4% | Constellation Brands beats expectations and maintains FY27 EPS guidance |
| LW Lamb Weston Holdings, Inc. | FY2027 Q1 · Calendar Q4 2026 | +27.8% | +7.5% | Lamb Weston raises FY2027 outlook as North America volume growth continues |
| MKC McCormick & Company, Incorporated | FY2026 Q3 · Calendar Q4 2026 | +13.9% | -4.9% | McCormick reports strong Q3 growth while U.S. volumes remain soft |
| CAG Conagra Brands, Inc. | FY2027 Q1 · Calendar Q3 2026 | +44.4% | -4.9% | Conagra maintains outlook while increasing brand investment and simplifying SKUs |
| COST Costco Wholesale Corporation | FY2026 Q4 · Calendar Q3 2026 | +3.2% | +2.9% | Costco’s growth broadens as warehouses and digital sales accelerate |
Latest beats and misses
Who reports nextBeat on EPS
Get the TAP recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-30T00:03:07.291072+00:00
- Polygon adjusted daily market bars · 2026-10-13T14:30:45.276114+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-13T14:30:45.273409+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-13. For educational purposes only; not investment advice.